Blood cancers

Checkpoint inhibitors may sensitise patients with refractory NHL to improve responses

Checkpoint inhibitors may help sensitise relapsed/refractory non-Hodgkin lymphoma (NHL) to subsequent chemotherapy, according to US researchers. The retrospective study analysed data from 59 patients who received checkpoint blockade as a second or later line therapy between 2012 and 2017 and subsequently received systemic therapy due to disease progression. Lymphoma subtypes were mostly DLBCL (40%), follicular ...

Already a member?

Login to keep reading.

© 2020 the limbic